tiprankstipranks
pc:tubul

Tubulis

Munich, Bayern 81377, DE
https://www.tubulis.com/
Tubulis is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) with enhanced biophysical properties for effective tumor targeting and prolonged anti-tumor activity. The company's lead ADC candidates, TUB-040 and TUB-030, are in clinical evaluation for high-need solid tumor indications, including ovarian cancer and lung adenocarcinomas. Tubulis leverages proprietary platform technologies to innovate ADC design, aiming to expand the therapeutic potential of this drug class for its pipeline, partners, and patients.

Leadership & Board

Current Number of Employees107
Current LinkedIn Followers15,360

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$344M
Total Amount Raised$344M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$344M
Latest Funding Amount$344M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation
Post-Money Valuation

Employee Trend

Tubulis had 107 employees as of April 6, 2026. The number of employees increased by 1 (0.94%) week-over-week.
107Latest Employee Count
1(0.94%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Tubulis had 15,360 followers as of April 6, 2026. The number of followers increased by 304 (2.02%) week-over-week.
15,360Latest Followers Count
304(2.02%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Main Enterprise Clients

A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 30, 2025
Series C
$344.00M

Investors

Related News and Analysis